Quince Therapeutics, Inc. (QNCX) Earning

$1.02

south_east
-$0.1 (-8.93%)
Day's range
$0.99
Day's range
$1.1
QNCX Earnings Estimates and Actuals by Quarter$2$2$1$1$0$0-$1-$1Q2 2024Q2 2024Q4 2024Q4 2024Q2 2025Q2 2025Q4 2025Q4 2025Q2 2026Q2 2026Q4 2026Q4 2026Q2 2027Q2 2027Q4 2027Q4 2027Q2 2028Q2 2028Q4 2028Q4 2028
Actual EPS
Download SVG
Download PNG
Download CSV

Quince Therapeutics, Inc. Analyst EPS Estimates

Quarter Number of Estimates Low Estimate High Estimate Average Estimate
Q1 2025 1 -$0.22 -$0.22 -$0.22
Q2 2025 1 -$0.22 -$0.22 -$0.22
Q3 2025 1 -$0.19 -$0.19 -$0.19
Q4 2025 1 -$0.17 -$0.17 -$0.17
Q1 2026 1 -$0.24 -$0.24 -$0.24
Q2 2026 1 -$0.25 -$0.25 -$0.25
Q3 2026 1 -$0.28 -$0.28 -$0.28
Q4 2026 1 -$0.29 -$0.29 -$0.29
Q1 2027 1 $0.05 $0.05 $0.05
Q2 2027 1 $0.06 $0.06 $0.06
Q3 2027 1 $0.05 $0.05 $0.05
Q4 2027 1 $0.05 $0.05 $0.05
Q1 2028 1 $0.63 $0.63 $0.63
Q2 2028 1 $0.65 $0.65 $0.65
Q3 2028 1 $0.64 $0.64 $0.64
Q4 2028 1 $0.66 $0.66 $0.66

Quince Therapeutics, Inc. Earnings Date And Information

Quince Therapeutics, Inc. last posted its earnings results on Monday, March 24th, 2025. The company reported $-0.28 earnings per share for the quarter, missing analysts' consensus estimates of $-0.19 by $0.09. The company had revenue of 168,000 for the quarter and had revenue of 0 for the year. Quince Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.31 diluted earnings per share) and currently has a price-to-earnings ratio of -0.78. Quince Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based on prior year's report dates.

Quince Therapeutics, Inc. Earnings History by Quarter

Date Quarter Consensus Estimate Reported EPS Beat/Miss Revenue Estimate Actual Revenue
03/24/2025 Q4 2024 -$0.19 $1.03 1.22 $168,000 $168,000
11/13/2024 Q3 2024 -$0.15 -$0.13 0.02 $0 $0
08/13/2024 Q2 2024 N/A -$0.64 N/A $0 $0
05/13/2024 Q1 2024 N/A -$0.26 N/A N/A $0
04/01/2024 Q4 2023 N/A -$0.22 N/A N/A $36,000
09/29/2023 Q3 2023 N/A -$0.15 N/A N/A $0
08/03/2023 Q2 2023 N/A -$0.14 N/A N/A $0
05/15/2023 Q1 2023 -$0.31 -$0.34 -0.03 N/A $0
03/15/2023 Q4 2022 -$0.29 -$0.16 0.13 N/A $0
11/09/2022 Q3 2022 -$0.28 -$0.23 0.05 N/A $0
08/09/2022 Q2 2022 -$0.74 -$0.51 0.23 N/A $0
05/10/2022 Q1 2022 -$0.55 -$0.71 -0.16 N/A $0
03/01/2022 Q4 2021 -$0.65 -$0.79 -0.14 N/A $0
10/29/2021 Q3 2021 -$0.74 -$0.73 0.01 N/A $0
08/06/2021 Q2 2021 -$0.76 -$0.74 0.02 N/A $0
05/06/2021 Q1 2021 -$0.72 -$0.78 -0.06 N/A $0
03/01/2021 Q4 2020 -$0.73 -$0.70 0.03 N/A $0
11/12/2020 Q3 2020 -$0.62 -$0.73 -0.11 N/A $0
08/14/2020 Q2 2020 -$0.62 -$0.60 0.02 N/A $0
05/12/2020 Q1 2020 -$0.44 -$0.61 -0.17 N/A $0

Quince Therapeutics, Inc. Earnings: FAQ's

Quince Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based offlast year's report dates.

The conference call for Quince Therapeutics, Inc.'s latest earnings report can be listened to online.

The conference call transcript for Quince Therapeutics, Inc.'s latest earnings report can be read online.

Quince Therapeutics, Inc. (:QNCX) has a recorded net income of $-56,828,000.Quince Therapeutics, Inc. has generated $-1.31 earnings per share over the last four quarters.

Quince Therapeutics, Inc. (:QNCX) has a price-to-earnings ratio of -0.78 and price/earnings-to-growth ratio is -0.01.

Portfolio Sync
Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED